Sigma Planning Corp’s ImmunityBio IBRX Stock Holding History

Sigma Planning Corp’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166K	Buy	19,015 +1,300	+7%	+$9.84K	﹤0.01%	1360
2026 Q1	$136K	Buy	17,715 +715	+4%	+$4.89K	﹤0.01%	1268
2025 Q4	$33.7K	Hold	17,000	–	–	﹤0.01%	1286
2025 Q3	$41.8K	Hold	17,000	–	–	﹤0.01%	1280
2025 Q2	$44.9K	Hold	17,000	–	–	﹤0.01%	1233
2025 Q1	$51.2K	Hold	17,000	–	–	﹤0.01%	1183
2024 Q4	$43.5K	Hold	17,000	–	–	﹤0.01%	1149
2024 Q3	$63.2K	Sell	17,000 -795	-4%	-$3.68K	﹤0.01%	1183
2024 Q2	$112K	Buy	17,795 +4,875	+38%	+$32.1K	﹤0.01%	1132
2024 Q1	$69.4K	Buy	+12,920	New	+$58.5K	﹤0.01%	1189
2023 Q4	–	Sell	-11,050	Closed	-$18.7K	–	1005
2023 Q3	$18.7K	Hold	11,050	–	–	﹤0.01%	1180
2023 Q2	$30.7K	Hold	11,050	–	–	﹤0.01%	1180
2023 Q1	$20.1K	Hold	11,050	–	–	﹤0.01%	1280
2022 Q4	$56K	Buy	11,050 +300	+3%	+$1.65K	﹤0.01%	1226
2022 Q3	$53K	Hold	10,750	–	–	﹤0.01%	1216
2022 Q2	$40K	Buy	10,750 +300	+3%	+$1.21K	﹤0.01%	1257
2022 Q1	$59K	Buy	+10,450	New	+$64.1K	﹤0.01%	1333

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sigma Planning Corp's IBRX Position: Q2 2026 in Review

Sigma Planning Corp increased its ImmunityBio (IBRX) stake by 7.3% in Q2 2026, buying an estimated $9.84K and bringing the position to 19,015 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Sigma Planning Corp first reported a position in IBRX in Q1 2022 and has held it in 17 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Sigma Planning Corp held 19,015 shares of ImmunityBio worth $166K as of Q2 2026.
Sigma Planning Corp bought 1,300 ImmunityBio shares in Q2 2026, an estimated $9.84K.
ImmunityBio made up ﹤0.01% of Sigma Planning Corp's portfolio in Q2 2026, its #1360 holding.
Sigma Planning Corp first reported a position in ImmunityBio in Q1 2022 and has held it in 17 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.